uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE)

Seeking Alpha·Jun 17

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

There are conflicting reports about the impact of the FDA's latest stance on uniQure's Huntington's disease treatment. Some outlets indicate that the FDA's decision has sent uniQure's stock soaring, while others report that the stock has crashed due to a rejected early approval path. The company has also been involved in a public offering of ordinary shares, with reported amounts varying.

Full coverage

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

Fierce Biotech·Mar 2

What Triggered uniQure's Sudden Stock Plunge

Kavout | AI·Mar 1

FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy

BioSpace·Dec 4

UniQure files $150M proposed public offering of ordinary shares

MSN·Jun 22

uniQure Stock Surges 76% on FDA Breakthrough for Huntington's Gene Therapy AMT-130

International Business Times Australia·Jun 18

View original report at Seeking Alpha ↗

Fetching the latest headlines…